
Stephen H Leppla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/111542/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor. Science, 1998, 280, 734-737.	12.6	992
2	Crystal structure of the anthrax toxin protective antigen. Nature, 1997, 385, 833-838.	27.8	763
3	Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Molecular Microbiology, 1994, 13, 1093-1100.	2.5	312
4	Anthrax Lethal Factor Cleavage of Nlrp1 Is Required for Activation of the Inflammasome. PLoS Pathogens, 2012, 8, e1002638.	4.7	275
5	Anthrax Pathogenesis. Annual Review of Microbiology, 2015, 69, 185-208.	7.3	230
6	Cellular and systemic effects of anthrax lethal toxin and edema toxin. Molecular Aspects of Medicine, 2009, 30, 439-455.	6.4	210
7	The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Structural and Molecular Biology, 2004, 11, 60-66.	8.2	182
8	Anthrax lethal and edema toxins in anthrax pathogenesis. Trends in Microbiology, 2014, 22, 317-325.	7.7	178
9	Cloning of the protective antigen gene of Bacillus anthracis. Cell, 1983, 34, 693-697.	28.9	153
10	Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12424-12429.	7.1	149
11	Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin. Journal of Biological Chemistry, 2001, 276, 17976-17984.	3.4	147
12	Inflammasome Sensor NLRP1 Controls Rat Macrophage Susceptibility to Toxoplasma gondii. PLoS Pathogens, 2014, 10, e1003927.	4.7	127
13	Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 657-662.	7.1	122
14	Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. Journal of Leukocyte Biology, 2016, 99, 189-199.	3.3	118
15	Optimized Production and Purification of Bacillus anthracis Lethal Factor. Protein Expression and Purification, 2000, 18, 293-302.	1.3	114
16	Anthrax Lethal Factor Cleaves Mouse Nlrp1b in Both Toxin-Sensitive and Toxin-Resistant Macrophages. PLoS ONE, 2012, 7, e49741.	2.5	112
17	Inflammasome Sensor Nlrp1b-Dependent Resistance to Anthrax Is Mediated by Caspase-1, IL-1 Signaling and Neutrophil Recruitment. PLoS Pathogens, 2010, 6, e1001222.	4.7	110
18	Oligomerization of Anthrax Toxin Protective Antigen and Binding of Lethal Factor during Endocytic Uptake into Mammalian Cells. Infection and Immunity, 1999, 67, 1853-1859.	2.2	105

#	Article	IF	CITATIONS
19	Development of an improved vaccine for anthrax. Journal of Clinical Investigation, 2002, 110, 141-144.	8.2	103
20	Key tissue targets responsible for anthrax-toxin-induced lethality. Nature, 2013, 501, 63-68.	27.8	101
21	Susceptibility to Anthrax Lethal Toxin-Induced Rat Death Is Controlled by a Single Chromosome 10 Locus That Includes rNlrp1. PLoS Pathogens, 2010, 6, e1000906.	4.7	86
22	Genome Engineering in <i>Bacillus anthracis</i> Using Cre Recombinase. Infection and Immunity, 2006, 74, 682-693.	2.2	77
23	Anthrax and the inflammasome. Microbes and Infection, 2012, 14, 392-400.	1.9	77
24	Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature. Journal of Biological Chemistry, 2008, 283, 529-540.	3.4	72
25	Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and Rats. Infection and Immunity, 2007, 75, 5175-5184.	2.2	71
26	Development of an improved vaccine for anthrax. Journal of Clinical Investigation, 2002, 110, 141-144.	8.2	71
27	Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nature Biotechnology, 2005, 23, 725-730.	17.5	62
28	The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS). PLoS Pathogens, 2009, 5, e1000456.	4.7	58
29	Role of N-Terminal Amino Acids in the Potency of Anthrax Lethal Factor. PLoS ONE, 2008, 3, e3130.	2.5	53
30	A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins. Protein Expression and Purification, 2011, 80, 80-90.	1.3	53
31	Imaging specific cell-surface proteolytic activity in single living cells. Nature Methods, 2006, 3, 259-261.	19.0	51
32	Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins, 2016, 8, 197.	3.4	46
33	A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Molecular Cancer Therapeutics, 2006, 5, 2556-2562.	4.1	45
34	Solid tumor therapy by selectively targeting stromal endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4079-87.	7.1	39
35	Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude Mice. Clinical Cancer Research, 2006, 12, 7437-7443.	7.0	38
36	Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1. FEBS Letters, 1995, 365, 95-97.	2.8	37

#	Article	IF	CITATIONS
37	Selection of Anthrax Toxin Protective Antigen Variants That Discriminate between the Cellular Receptors TEM8 and CMG2 and Achieve Targeting of Tumor Cells. Journal of Biological Chemistry, 2007, 282, 9834-9845.	3.4	36
38	Engineering Anthrax Toxin Variants That Exclusively Form Octamers and Their Application to Targeting Tumors. Journal of Biological Chemistry, 2013, 288, 9058-9065.	3.4	35
39	Antitumor efficacy of a urokinase activation–dependent anthrax toxin. Molecular Cancer Therapeutics, 2006, 5, 89-96.	4.1	34
40	PapR peptide maturation: role of the NprB protease in <i>Bacillus cereus</i> 569 PlcR/PapR global gene regulation. FEMS Immunology and Medical Microbiology, 2009, 55, 361-377.	2.7	34
41	Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages. Biochemical and Biophysical Research Communications, 2010, 398, 785-789.	2.1	34
42	Structural basis of R-loop recognition by the S9.6 monoclonal antibody. Nature Communications, 2022, 13, 1641.	12.8	32
43	Systematic Urokinase-Activated Anthrax Toxin Therapy Produces Regressions of Subcutaneous Human Non–Small Cell Lung Tumor in Athymic Nude Mice. Cancer Research, 2007, 67, 3329-3336.	0.9	31
44	A New Minimal Replicon of <i>Bacillus anthracis</i> Plasmid pXO1. Journal of Bacteriology, 2009, 191, 5134-5146.	2.2	31
45	Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine, 2001, 20, 789-796.	3.8	30
46	Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma. Molecular Cancer Therapeutics, 2010, 9, 190-201.	4.1	28
47	Efficient Targeting of Head and Neck Squamous Cell Carcinoma by Systemic Administration of a Dual uPA and MMP-Activated Engineered Anthrax Toxin. PLoS ONE, 2011, 6, e20532.	2.5	27
48	Anthrax Toxin Uptake by Primary Immune Cells as Determined with a Lethal Factor-β-Lactamase Fusion Protein. PLoS ONE, 2009, 4, e7946.	2.5	26
49	Lipoprotein biosynthesis by prolipoprotein diacylglyceryl transferase is required for efficient spore germination and full virulence of <i>Bacillus anthracis</i> . Molecular Microbiology, 2012, 83, 96-109.	2.5	25
50	Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2through an AtxA-dependent mechanism. BMC Genomics, 2014, 15, 229.	2.8	20
51	The diphthamide modification on elongation factor-2 renders mammalian cells resistant to ricin. Cellular Microbiology, 2008, 10, 1687-1694.	2.1	19
52	Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during <i>In vitro</i> Morphogenesis. Molecular Cancer Research, 2009, 7, 452-461.	3.4	19
53	Anthrax Toxin-Mediated Delivery of the Pseudomonas Exotoxin A Enzymatic Domain to the Cytosol of Tumor Cells via Cleavable Ubiquitin Fusions. MBio, 2013, 4, e00201-13.	4.1	19
54	Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities. Toxicology and Applied Pharmacology, 2014, 279, 220-229.	2.8	19

#	Article	IF	CITATIONS
55	Bacillus anthracis Virulence Regulator AtxA Binds Specifically to the <i>pagA</i> Promoter Region. Journal of Bacteriology, 2019, 201, .	2.2	17
56	Genome engineering in Bacillus anthracis using tyrosine site-specific recombinases. PLoS ONE, 2017, 12, e0183346.	2.5	17
57	Methylation-dependent DNA restriction in Bacillus anthracis. Gene, 2012, 494, 44-50.	2.2	16
58	Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting. Journal of Biological Chemistry, 2016, 291, 22021-22029.	3.4	15
59	Hfqs in <scp><i>B</i></scp> <i>acillus anthracis</i> : Role of protein sequence variation in the structure and function of proteins in the <scp>H</scp> fq family. Protein Science, 2015, 24, 1808-1819.	7.6	14
60	Anthrax Edema Factor Toxicity Is Strongly Mediated by the N-end Rule. PLoS ONE, 2013, 8, e74474.	2.5	13
61	Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic Cells. Molecular Neurobiology, 2019, 56, 3393-3403.	4.0	13
62	Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden. Oncotarget, 2015, 6, 33534-33553.	1.8	12
63	Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality. Nature Microbiology, 2020, 5, 1464-1471.	13.3	9
64	Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel. Investigational New Drugs, 2013, 31, 206-212.	2.6	8
65	Identification of Three Noncontiguous Regions on Bacillus anthracis Plasmid pXO1 That Are Important for Its Maintenance. Journal of Bacteriology, 2014, 196, 2921-2933.	2.2	7
66	Characterization of a Chinese Hamster Ovary Cell Mutant Having a Mutation in Elongation Factor-2. PLoS ONE, 2010, 5, e9078.	2.5	6
67	Tumor Imaging Using Radiolabeled Matrix Metalloproteinase–Activated Anthrax Proteins. Journal of Nuclear Medicine, 2019, 60, 1474-1482.	5.0	6
68	Recombinant expression and purification of a tumor-targeted toxin in Bacillus anthracis. Biochemical and Biophysical Research Communications, 2013, 430, 150-155.	2.1	5
69	Effect of late endosomal DOBMP lipid and traditional model lipids of electrophysiology on the anthrax toxin channel activity. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 2192-2203.	2.6	4
70	Exploring the Nature of Cationic Blocker Recognition by the Anthrax Toxin Channel. Biophysical Journal, 2019, 117, 1751-1763.	0.5	4
71	Hydrophobic Gating and 1/f Noise of the Anthrax Toxin Channel. Journal of Physical Chemistry B, 2021, 125, 5466-5478.	2.6	4
72	lmaging of anthrax intoxication in mice reveals shared and individual functions of surface receptors CMG-2 and TEM-8 in cellular toxin entry. Journal of Biological Chemistry, 2022, 298, 101467.	3.4	4

#	Article	IF	CITATIONS
73	Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	4
74	Effect of over expressing protective antigen on global gene transcription in Bacillus anthracis BH500. Scientific Reports, 2018, 8, 16108.	3.3	3
75	Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA. Nuclear Medicine and Biology, 2019, 72-73, 49-54.	0.6	3
76	Characterization of the NLRP1 inflammasome response in bovine species. Innate Immunity, 2020, 26, 301-311.	2.4	3
77	The IntXO-PSL Recombination System Is a Key Component of the Second Maintenance System for Bacillus anthracis Plasmid pXO1. Journal of Bacteriology, 2016, 198, 1939-1951.	2.2	2
78	Anthrax Lethal Factor. , 2013, , 1257-1261.		2
79	Bismaleimide crossâ€linked anthrax toxin forms functional octamers with high specificity in tumor targeting. Protein Science, 2019, 28, 1059-1070.	7.6	1
80	A potent tumor-selective ERK pathway inactivator with high therapeutic index. , 2022, 1, .		1
81	Anthrax lethal factor. , 2004, , 781-783.		Ο